Cerecor Engages SunTrust Robinson Humphrey to Assist with Review of Strategic Alternatives

Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value and has engaged SunTrust Robinson Humphrey, Inc. (“SunTrust”) as its exclusive financial advisor for this process. Potential strategic alternatives that may be explored or evaluated as part of this process include an acquisition, merger, business combination or other strategic transaction. The Company has not made a decision to pursue any specific transaction or other strategic alternative, and there can be no assurance that this process will result in any such transaction.
“The engagement of SunTrust adds to our ongoing efforts to explore various options for Cerecor,” said Dr. Uli Hacksell, President and Chief Executive Officer of Cerecor.

This entry was posted in Recent Development News: Q1 - 2017, Recent Developments. Bookmark the permalink.
Read Full Article »